Efficacy and Safety of Hydroxychloroquine in Patients with IgA Nephropathy: A Meta-Analysis

ABSTRACT

Aim: The purpose of this study was to determine efficacy and safety of hydroxychloroquine (HCQ) for patients with IgA nephropathy (IgAN). Methods: PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, Wanfang database, Chinese National Knowledge Infrastructure and VIP database up to February 2023 were searched for associated studies comparing HCQ with any other nonHCQ for treating IgAN. The effects of proteinuria, a 50% decrease in proteinuria, estimated glomerular filtration rate (eGFR) and adverse events in patients with IgAN were examined in a meta-analysis. Data were extracted and pooled using RevMan 5.3. Results: Three randomized controlled trials (RCTs), two retrospective and two prospective studies (675 patients) that matched our inclusion criteria were identified. Compared with a control group, HCQ significantly reduced proteinuria (mean difference (MD) −0.26, 95% confidence interval (CI) −0.44 to −0.08, p < 0.01). Patients receiving HCQ plus renin-angiotensin system inhibitors (RASSi) had a better efficacy in proteinuria alleviation and a 50% decrease in proteinuria compared with control groups (MD −0.38, 95% CI −0.50 to −0.25, p < 0.001 and relative risk (RR) = 3.31, 95% CI 1.73 to 6.36, p < 0.001). No appreciable variations were observed in eGFR between HCQ groups and control groups in treating patients with IgAN (MD −2.00, 95% CI −4.36 to 0.36, p = 0.10). Moreover, no serious adverse events were observed during HCQ treatment. Conclusions: Our results indicate HCQ is an efficient, secure treatment for IgAN (AU)